Bruce Keyt - Mar 30, 2022 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Chief Scientific Officer
Signature
/s/ Misbah Tahir, by power of attorney
Stock symbol
IGMS
Transactions as of
Mar 30, 2022
Transactions value $
-$206,750
Form type
4
Date filed
4/1/2022, 08:16 PM
Previous filing
Mar 17, 2022
Next filing
Apr 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Options Exercise $6.98K +7.5K +18.74% $0.93* 47.5K Mar 30, 2022 Direct F1
transaction IGMS Common Stock Sale -$214K -7.5K -15.78% $28.50 40K Mar 30, 2022 Direct F1, F2
holding IGMS Common Stock 1.01K Mar 30, 2022 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGMS Stock Option (right to buy) Options Exercise $0 -7.5K -5.22% $0.00 136K Mar 30, 2022 Common Stock 7.5K $0.93 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $28.18 to $29.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held directly by the reporting person's spouse.
F4 The shares subject to the option are vested and exercisable as of the date hereof.